RVMD Revolution Medicines, Inc. stock chart & analysis

Conviction 54HealthcareScan · Fri, Nov 6, 2026

Revolution Medicines, Inc. (RVMD) closed at $192.28 (+8.24%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 50, RS Rating 98, -14.3% from its 52-week high, +141.3% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

RVMD$192.28+8.24%

ResistanceSupportVol 14Insider sell

Loading chart…

Revolution Medicines, Inc.Biological Products, (No Diagnostic Substances)www.revmed.com ↗

Price192.28

Change+8.24%

Gap+4.50%

Rel volume3.29×

Avg volume2.39M

Avg $ vol449.6M

SMA 20189.16

SMA 50196.88

SMA 200157.82

Price vs 50-2.39%

Price vs 200+21.77%

MA stackmixed

50/200 cross—

Supertrenddown · 207.89

RSI (14)50

MACD hist0.55

MACD crossbull · 6d

Stoch %K / %D44 / 44

ADX (14)16

+DI / −DI16 / 22

RSI divergence—

MACD divergence—

ATR %5.48%

ADR %5.24%

52w high224.31

52w low58.91

From 52w high-14.32%

Above 52w low+226.20%

New 52w highNo

SqueezeOn · 2d

Bollinger width11.84%

%B0.64

Donchian pos45.83%

Donchian high211.41

Donchian low175.91

AVWAP (52w high)196.17

vs AVWAP high-2.04%

AVWAP (52w low)139.10

vs AVWAP low+38.16%

OBV trendFlat

Chaikin MF (20)-0.04

Today vs 20d3.29×

Avg vol (14d)2.44M

Avg vol (20d)2.39M

Avg $ vol (20d)449.6M

Market cap41.57B

RS Rating98 / 99

RS 3m (vs SPY)-2.28%

RS 6m (vs SPY)+35.82%

RS line new highNo

Trend template6/8

Technical rank80.9

1 week+0.45%

1 month+2.16%

3 months-7.15%

6 months+35.52%

1 year+223.86%

YTD+141.28%

P/E-36.74

P/B17.31

P/S—

P/FCF-45.49

EPS-5.95

Div yield—

ROE-47.11%

ROA-26.29%

Debt/Eq—

Current8.36

EV/EBITDA-34.86

Gross margin—

Net margin—

Rev growth—

EPS growth-88.52%

Price target268.21

Target upside39.56%

Analyst ratingBuy

Institutional112.52%

Ent. value40.95B

Revenue197.56M

Net income-407.46M

Gross profit197.23M

Free cash flow-913.73M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out212.6M

Employees883

ListedThu, Feb 13, 2020

Free float152.8M

Float %79.0%

Short interest—

Days to cover—

Short volume63.6%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est−$1.90 vs −$2.34

Last surprise+18.8% beat

Setup gradeD

Conviction54 / 100

Pattern quality—

Tech rank80.9 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance211.20

Support178.20

Days since event—

Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

RVMD technical analysis

Trend

RVMD's moving averages are mixed — no clean uptrend or downtrend. It closed 2.4% below the 50-day ($196.88) and 21.8% above the 200-day ($157.82). ADX(14) at 16 points to a weak trend — more range than direction. It meets 6 of 8 trend-template criteria.

Momentum

RSI(14) is 50, in the bullish half of its range. MACD crossed above its signal line 6 sessions ago. Its RS Rating of 98 puts its weighted 12-month performance ahead of about 98% of the US market.

Volume and volatility

Volume on the latest session ran 3.3× its 20-day average. It trades about $449.6M a day on average. ATR(14) is $10.53, 5.5% of price — its typical daily range. Bollinger Bands are in a squeeze (2 sessions) — volatility is compressed.

Key levels

The chart pattern's support is $178.20 and its resistance $211.20. The 52-week range is $58.91 to $224.31; price is 14.3% below the high and 226.2% above the low. The VWAP anchored at the 52-week high is $196.17, above price.

Performance

RVMD returned +0.4% (1 week), +2.2% (1 month), -7.1% (3 months), +35.5% (6 months), +223.9% (1 year), +141.3% (year to date).

About Revolution Medicines, Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Biological Products, (No Diagnostic Substances) · Listed 2020 · 883 employees

Insider activity

SEC Form 4 transactions in RVMD · open-market 6 sells

Insider	Side	Shares	Value	Traded	Filed
Mancini Anthony See Remarks · Common Stock · 2026-10-26	Exercise	2.31K	$78K	2026-10-26	2026-10-28
Mancini Anthony See Remarks · Common Stock · 2026-10-26	Sell	2.31K	$432K	2026-10-26	2026-10-28
Mancini Anthony See Remarks · Stock Option (Right to Buy) · 2026-10-26	Exercise	2.31K	—	2026-10-26	2026-10-28
Cislini Jeff SVP & General Counsel · Common Stock · 2026-09-25	Sell	765	$159K	2026-09-25	2026-09-29
Kelsey Stephen Michael See Remarks · Common Stock · 2026-09-11	Exercise	52.5K	$2.2M	2026-09-11	2026-09-15
Kelsey Stephen Michael See Remarks · Common Stock · 2026-09-11	Exercise	40.03K	$1.6M	2026-09-11	2026-09-15
Kelsey Stephen Michael See Remarks · Common Stock · 2026-09-11	Sell	800	$159K	2026-09-11	2026-09-15
Kelsey Stephen Michael See Remarks · Common Stock · 2026-09-11	Sell	11.83K	$2.4M	2026-09-11	2026-09-15
Kelsey Stephen Michael See Remarks · Common Stock · 2026-09-11	Sell	13.37K	$2.7M	2026-09-11	2026-09-15
Kelsey Stephen Michael See Remarks · Common Stock · 2026-09-11	Sell	21.45K	$4.3M	2026-09-11	2026-09-15

SEC filings

EDGAR filings in RVMD · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.